• Non ci sono risultati.

scarica la Lettera di intenti

N/A
N/A
Protected

Academic year: 2022

Condividi "scarica la Lettera di intenti"

Copied!
4
0
0

Testo completo

(1)

Call for applications Letter of intent

Name of the coordinator Click here to enter text

Specialty Click here to enter text

Unit or Department Click here to enter text Name and address of the

hospital/institution

Click here to enter text

Phone number Click here to enter text

E-mail Click here to enter text

Medical Oncologist, Postgraduated School in Medical Oncology, Phd Oncology

Click here to enter text

AIOM member

Yes ☐ No ☐

(Non-members are eligible for the application only if they have applied for AIOM membership before the deadline of this project application).

Research domain

-Organ, tumor location : -Others:

Click here to enter text Click here to enter text Level of funding required (Euros) Click here to enter text Project title

Click here to enter text

(2)

Name of the methodologist (if any) Click

here to enter text Name and address of the hospital Click here to enter text

Phone number Click here to enter text

E-mail Click here to enter text

Anticipated number of recruiting centers (approximate)

Click here to enter text

Surname Name Town Hospital

/Institution E-mail Phone

1 2 3 4 5

References

List of the main publications from literature (5 maximum) justifying the project in the national and international context

Click here to enter text

Rationale (max 300 words) Click here to enter text

Originality and innovative aspects Click here to enter text

Main objective Click here to enter text

Secondary objectives Click here to enter text

The exploratory objectives are (if any): Click here to enter text Primary end point

Click here to enter text

(3)

Secondary end points Click here to enter text

Study population (if needed in the study design) Main inclusion criteria

Click here to enter text Main exclusion criteria Click here to enter text Design

Systematic reviews - Meta analysis Yes ☐ No ☐ Randomized clinical trial Yes ☐ No ☐

if yes: Open☐ Single blind ☐ Double blind☐

Non randomized trial ☐

Prospective cohort study ☐ Case-control study ☐ Cross-sectional study ☐ Retrospective cohort ☐ Administrative / hospital inpatient database research ☐ Modelisation ☐ Case series ☐ Pure preclinical studies☐ Others ☐ Please detail:

Click here to enter text If comparison groups : Click here to enter text

(4)

Duration (the maximum duration is 2 years) Click here to enter text

Statistical design

Total number of scheduled patients / observations to be recruited (if any) Click here to enter text

Participation of a research network (if any) Click here to enter text

Others aspects to insure the feasibility of the project Click here to enter text

Expected patient or public health benefit (max 300 words) Click here to enter text

Riferimenti

Documenti correlati

 CheckMate 057 (NCT01673867): Randomized, phase III trial of nivolumab vs docetaxel in patients with advanced non-SQ NSCLC..  Efficacy and safety of nivolumab in two

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease – A systematic literature review by a European panel of experts. Molecular